Answer: A Routine Surveillance inspection is typically announced and focuses on overall systems coverage to ensure ongoing compliance. A “For-Cause” inspection is almost always unannounced and is triggered by a specific event, such as a product recall, consumer complaint, or whistleblower report. We help you prepare for both scenarios.
We typically schedule audits with 2-3 weeks’ notice, but we can often accommodate urgent requests (such as “For-Cause” readiness) within 72 hours depending on consultant availability.
Yes, our team includes former FDA investigators and industry veterans with decades of experience, giving us unique insight into what inspectors are looking for today.
Absolutely. We have a global network of consultants who can assist with FDA foreign inspections, as well as inspections by other regulatory bodies (EMA, MHRA, etc.) in Europe, Asia, and South America.
Yes. If you receive a Form 483 (Observation of Inspectional Misconduct), we help you draft a robust response letter to the FDA within the required 15-day window. We also help design and implement a CAPA (Corrective and Preventive Action) plan to fix the systemic issues.
We perform a full range of GxP audits, including GMP (Manufacturing), GCP (Clinical), GLP (Laboratory), and vendor qualification audits to ensure your supply chain is compliant.
First, activate your “Inspection Readiness Plan” immediately. Ensure your front-office staff knows who to notify. Quality Resource Solutions can provide on-site or remote support during the inspection to help manage requests, scribe, and coach your subject matter experts (SMEs).
We conduct comprehensive “Mock PAI” audits that mimic the actual FDA process. Our consultants review your development data, data integrity, and manufacturing readiness to identify gaps before the real inspectors arrive, ensuring your product application isn’t delayed.
Ex-FDA inspector on staff
100+ global auditors
Lower travel costs via local auditors
Faster scheduling
AI-enhanced processes
15+ years supporting global sponsors, CROs, and CMOs
